- 1 The prevalence of post COVID-19 condition (PCC) and a simple risk scoring tool for PCC
- 2 screening on Bonaire, Caribbean Netherlands: a retrospective cohort study.
- 3 Danytza SF Berry<sup>1</sup>\*, Thomas Dalhuisen<sup>1</sup>\*, Giramin Marchena<sup>2</sup>, Ivo Tiemessen<sup>3</sup>, Eveline Geubbels<sup>1</sup>
- 4 Loes Jaspers<sup>2</sup>
- 5 \*Joint first authorship.
- 6 Corresponding author: Loes Jaspers, <u>loesjaspers@gmail.com</u>

#### 7 Affiliations:

- 8 <sup>1</sup>National Institute for Public Health and the Environment, Centre for Infectious Disease Control,
- 9 Bilthoven, The Netherlands
- 10 <sup>2</sup> Public Health Department Bonaire, Public Entity of Bonaire, Caribbean Netherlands
- <sup>3</sup> Mobilito, Bonaire, Caribbean Netherlands
- 12

## 13 Acknowledgements:

- 14 We would like to thank Adrienn Vegh (General Practitioner) who served as a practical advisor on post
- 15 COVID-19 condition related primary care on Bonaire. Also, we would like to thank the team of
- 16 interviewers from Tempo, Bonaire, who carried out the telephone interviews, and CBS Bonaire for
- 17 their assistance in setting up training for the group of interviewers. Furthermore, we would like to
- 18 thank Alicia Xuan-Krijgsman (Public Health Department Bonaire) for assistance during the
- 19 preliminary phase of this study's design and Karin Cox (Public Health Department Bonaire) for
- 20 assisting in developing the call list of cases eligible for inclusion in the study.

21

22

23

## 24 ABSTRACT

- 25 <u>Aim:</u> To assess the prevalence of post COVID-19 condition (PCC) on Bonaire and develop a practical
- risk scoring tool for PCC screening, using easily obtainable characteristics.
- 27 Methods: A retrospective cohort study of symptomatic SARS-CoV-2 cases were randomly sampled
- from Bonaire's case-registry and telephone interviewed between 15-November-2021 and 4-December-
- 29 2021. PCC patients had a PCR-positive SARS-CoV-2 test (1-March-2020 and 1-October-2021) and
- 30 self-attributed at least one symptom lasting over four weeks to their infection. Multivariate logistic
- 31 regression was used to derive a risk formula to develop a practical risk scoring tool.
- 32 **<u>Results:</u>** Out of 414 cases, 160 (39%) were PCC patients. Fifty-three patients were unrecovered
- 33 (median illness duration 250 days (IQR 34)). Of recovered patients, 35% experienced symptoms for at
- 34 least 3 months after disease onset. PCC prevalence was highest among females (38%), 40-59 year-olds
- 35 (40%), morbidly obese (31%) and hospitalized patients (80%). A PCC risk scoring tool using age, sex,
- 36 presence of comorbidities, and acute phase hospitalization or GP visit had an area-under-the-curve
- 37 (AUC) of 0.68 (95% CI 0.63-0.74). Adding smoking, alcohol use, BMI, education level, and number of
- acute phase symptoms increased the AUC to 0.79 (95% CI 0.74- 0.83). Subgroup analyses of non-
- 39 hospitalized patients (n=362) resulted in similar AUCs.
- 40 <u>Conclusion:</u> Thee estimated prevalence of PCC on Bonaire was 39%. Moreover, easily obtainable
- 41 patient characteristics can be used to build a risk scoring tool for PCC with acceptable discriminatory
- 42 power. After external validation, this tool could aid the development of healthcare interventions in low
- 43 resource settings to identify patients at risk for PCC.
- 44 Keywords: post COVID-19 condition; long-covid; Bonaire; risk-scoring tool; prevalence, cohort
- 45 study, Caribbean Netherlands

## 46 Key messages:

## 47 What is already known on this topic:

48	•	An increasing number of studies show that varying proportions of COVID-19 patients are left
49		with prolonged health issues, including persistence of symptoms such as fatigue, shortness of
50		breath, loss of muscle strength, and concentration issues following the acute phase of COVID-
51		19.
52	•	Prevalence of this recently recognized medical syndrome, 'long-COVID' or 'post COVID-19
53		condition (PCC)', ranges between 37-49% in the European Netherlands, though there are no
54		reports of PCC prevalence in the Caribbean Netherlands to date.
55	What th	nis study adds:
56	•	We designed the first retrospective cohort study estimating the prevalence and characteristics
57		of PCC on Bonaire, Caribbean Netherlands and devised a simple risk scoring formula to
58		calculate PCC risk.
59	•	We found a PCC prevalence of 39% on Bonaire and describe a proof-of-concept risk scoring
60		tool with good discriminatory performance.
61	How the	is study might affect research, practice or policy:
62	•	Our study estimates PCC prevalence and describes disease and patient characteristics for
63		Bonaire. This is the first study providing these insights in the Caribbean; a region that has
64		been underrepresented in PCC research.
65	•	Furthermore, our study highlights the added benefit of registering sufficient patient
66		characteristics at the time of consultation for acute COVID-19 disease, for improved PCC
67		screening later on.
68	•	After external validation of our proof-of-concept study, this risk scoring tool could aid the
69		development of primary care and public health interventions and health communication
70		strategies in low resource settings for the identification of patients at risk for PCC.

## 71 INTRODUCTION

As of 11 January 2023, an estimated 660,378,145 confirmed COVID-19 cases including 6,691,495 72 73 deaths have been reported worldwide [1]. Although most cases fully recover shortly after the acute 74 infection, an increasing number of international studies suggest that varying proportions of patients are 75 left with prolonged health issues [2]. This recently recognized medical syndrome, 'long-COVID' or 76 'post COVID-19 condition (PCC)', includes persistence of symptoms like fatigue, shortness of breath, 77 loss of muscle strength, and concentration issues following the acute phase of COVID-19 [3-5]; much 78 like other post-infectious syndromes, where prolonged symptoms can occur in a remitting pattern due 79 to persistence of an infectious agent, such as Lyme disease or Q-fever [2, 5].

- In van der Maaden et al. (2023), a longitudinal study of PCC in the European Netherlands, 49% of COVID-19 cases reported symptoms three months after SARS-CoV-2 infection [6]. A study by Nivel showed 37% of Dutch COVID-19 patients visiting the GP three months after disease onset reported still experiencing at least one symptom [7]. These findings are roughly in line with a recent global pooled PCC prevalence estimate of 43% (95% CI, 39-46%), though untangling symptom attribution solely to SARS-CoV-2 infection remains challenging [2]. Furthermore, PCC prevalence appears higher among those hospitalized (54%, 95% confidence interval (CI) 44-63%) compared to non-hospitalized patients
- 87 (34%, 95% CI 24-46%) [2].
- 88 Since the start of the COVID-19 pandemic, Bonaire has seen various waves of SARS-CoV-2 infections. 89 Bonaire is an island in the Dutch Caribbean with 21,745 permanent residents in 2021 [8]. By 1 October 90 2021, 2,036 persons living or staying on the island had tested positive, of whom 57 were admitted to the 91 hospital and 19 passed away due to or with COVID-19 [9]. In May 2021, local general practitioners 92 (GPs) on the island raised concerns about the lack of knowledge on the burden and risk factors of PCC 93 among Caribbean populations and the impact of PCC on health systems in Caribbean settings. Local 94 practitioners hypothesized the prevalence and symptomatology of PCC may differ substantially from 95 that reported in Western settings due to the different health system context, demographics, and burden of non-communicable disease (NCD) on Bonaire [10-12]. Various studies have shown disparities 96 97 between different populations in COVID-19 risk and severity [13], though little remains known of how 98 these disparities translate into PCC outcomes and care [14, 15].
- 99 Besides gaining insights into the prevalence of PCC on Bonaire, practical and easy-to-use risk scoring 100 tools are needed to identify cases in low resource-settings that are at an increased risk of developing 101 PCC. Formal PCC diagnostics are lacking, and PCC consequently remains an underdiagnosed condition 102 even though timely diagnosis is needed to access appropriate insured care and treatment [15, 16]. Tools 103 that may identify those at an increased PCC risk can aid in increasing the proportion of PCC patients 104 that are formally diagnosed by healthcare providers in a timely matter. Ideally, these tools should require 105 only a limited number of inputs, which can be easily obtained by GPs. Therefore, in this study we aim

to assess the prevalence and characteristics of PCC on Bonaire and to develop a pragmatic risk scoring

107 tool using easily obtainable patient characteristics to identify patients at risk of developing PCC.

#### 108 METHODS

#### 109 Study design & setting

We designed a retrospective cohort study of individuals who tested positive for SARS-CoV-2 at the 110 111 public health department of Bonaire between the start of the pandemic and 1 October 2021 (Supplementary Figure 1). The public health department was the main facility on the island for 112 113 community testing. Testing was free of charge. The type of diagnostic tests used were in accordance 114 with the guidelines from the Dutch Ministry of Health at the time of testing and included approved PCR-115 or antigen tests. The study protocol was developed through a collaboration between researchers from 116 the Public Health Department on Bonaire and the National Institute for Public Health and the 117 Environment (RIVM, in European Netherlands). Data collection took place on Bonaire, and data 118 analysis was carried out by researchers from the RIVM in close virtual collaboration with the researchers 119 based on Bonaire.

## 120 Participants

121 Participant data was exported from HP Zone, the patient registration and outbreak management software 122 system used to register data about the notifiable cases throughout the COVID-19 pandemic on Bonaire. 123 Individuals were eligible for recruitment if they were a) permanent residents of Bonaire; b) symptomatic; 124 c) had a laboratory confirmed SARS-CoV-2 positive test result, and d) had contact details available at 125 the public health department. All eligible participants were assigned a number: 0 for patients 126 hospitalized for COVID-19 during the acute phase or randomly the number 1, 2, 3 or 4 for non-127 hospitalized patients. All patients hospitalized for COVID-19 during the acute phase were invited for 128 study participation. Thereafter, all the eligible participants in groups 1-4 were called, starting with 129 number 1, until enough participants were included to satisfy the required power threshold of the study. 130 This approach allowed us to incorporate a random element of sample selection and reaching enough 131 power for the study by calling all patients hospitalized for COVID-19 during the acute phase first. This 132 approach was chosen, given that on Bonaire, resources for the study completion were minimal, and we 133 wanted to assure maximum power for the study.

#### 134 Patient and public involvement

Local GPs were provided the opportunity to help design the questionnaire and to formulate research priorities. Preliminary results were shared with the public by Bonaire's Public Health Department through local media (radio and television) and a press briefing in the spring of 2022. Moreover, the results were discussed in a group session of health care and governmental professionals, including representatives of the GPs, the hospital, the health insurance office, and policy advisors of the local government. Remaining research needs were addressed, and where possible, integrated into the ongoing analyses.

Furthermore, COVID-19 patients were able to self-enroll in the study if they were not called by the interviewers, but felt the need to share their experiences. They were given a separate coding in the questionnaire, in order to distinguish the randomly selected from the self-selected participants. In the end, no patients opted to self-enroll in the study.

#### 146 **Case definitions and community controls**

147 A PCC patient was defined as "an individual with a laboratory confirmed SARS-CoV-2 positive test 148 result, of whom at least one symptom self-attributed to the experienced SARS-CoV-2 infection lasted 149 longer than four weeks" [17]. Cases with a laboratory confirmed SARS-CoV-2 positive test result, of 150 whom all symptoms self-attributed to the experienced SARS-CoV-2 infection lasted shorter than four 151 weeks were defined as non-PCC cases. A community control group was included to assess background 152 prevalence of symptoms. By doing so, we aimed to have a stronger basis to differentiate whether certain 153 results could be attributable to pre-existing underling disease, to a pandemic effect, or to the experienced 154 SARS-CoV-2 infection. During the telephone interview, SARS-CoV-2 positive cases were asked to 155 provide contact details of a community control, defined as "an individual who had not been a close 156 contact of the case during the infection phase, was of the same sex and similar age, was from outside 157 their household, and who they knew had not tested positive with SARS-CoV-2 until the moment of 158 interview". It was expected that this approach would result in more controls as opposed to recruiting 159 individuals who had tested negative at the island's testing facilities.

#### 160 Study size

The expected study size was calculated based on a desired alpha of 0.05, power of 80%, expected response rate of 70% and a conservatively estimated expected PCC prevalence of 20% at 4 weeks after acute infection. Therefore, a sample of roughly 600 COVID-19 patients would be needed to estimate the expected 20% prevalence of PCC with a 95% confidence interval of 6% width [17-23%]. In addition, a cohort of 200 self-reported SARS-CoV-2 negative individuals was invited in order to be able to compare the distribution of risk factors for and symptoms of PCC among COVID-19 patients with that of the general population. In total, we aimed to invite 800 individuals to participate in the study.

#### 168 Data collection

A questionnaire was designed based on 2021 PCC surveys from Nivel (Netherlands Institute for Health
Services Research), RIVM (Netherlands National Institute for Public Health and the Environment),
GGD Zuid Holland Zuid (Municipal Health Service South Holland), Radboud University Medical
Centre (UMC), and Maastricht & Hasselt University. Our questionnaire was developed for three groups:
those who did not have COVID-19 (community controls), those who did get infected with SARS-CoV2 but did not develop PCC (non-PCC cases), and those who developed PCC (PCC patients).
Survey questions focused on demographics, health status prior to the first outbreak, pre- and post-

175 Survey questions focused on demographics, health status prior to the first outbreak, pre- and post-176 infection COVID-19 vaccination status, hospitalization for acute COVID-19 symptoms, PCC symptoms

177 at the time of the interview, and healthcare utilization pre- and post-infection. The questionnaire was 178 reviewed for practical relevance by several local GPs. It was translated into the four main languages 179 spoken on Bonaire: Dutch, English, Papiamentu, and Spanish. Thereafter, the questionnaires were 180 uploaded into an online form using the data management program 'digitale checklisten.nl' [18]. It was 181 expected this approach would increase the response rate, taking local health literacy into consideration.

- expected this approach would increase the response rate, taking local health increasy into consider
- 182 No back translation procedure took place due to time constraints.
- 183 In collaboration with the employment agency Tempo [19], we developed a job vacancy and hired a team
- 184 of 30 local interviewers. In November 2021, they were trained to carry out telephone interviews by the
- research team of the Public Health Department and the Central Bureau of Statistics (CBS) Bonaire.

186 Eligible respondents were invited to participate in the study through a WhatsApp message, which 187 included information about the study and the informed consent statement (both in writing and as a voice 188 message recorded by a well-known Bonairean spokesperson). Verbal informed consent was obtained 189 and documented by the main interviewer prior to the start of the interview. Respondents were explained 190 the purpose of the study and that they could choose to resign from the interview at any time. A second 191 interviewer verified whether consent was given, prior to the first interviewer commencing the interview. 192 The second interviewer only confirmed whether the informed consent was given by the respondent. Data 193 was collected between 15 November and 4 December 2021 through telephone interviews of 194 approximately 20 minutes for community controls, 30 minutes for non-PCC cases, and 45 minutes for 195 PCC-patients. Eligible respondents were called inside and outside office hours to increase the likelihood 196 of being reached. Interviewers made three attempts to reach an eligible respondent, otherwise they were 197 registered as not reached on the call list. Data was directly entered into the online registry system 198 'digitale checklisten' by the interviewer.

## 199 Ethical approval

- The study protocol was sent to the Central Committee on Research Involving Human Subjects (CCMO Netherlands) [20], who confirmed on 8 October 2021 that the study did not require ethical approval due to its observational design. Patient data export necessary for participant selection was only extracted from HP zone after permission from the Dutch COVID-19 patient data protection unit at GGD GHOR
- 204 the Netherlands was given.

#### 205 Variables

- For this study, we defined PCC as "the presence of at least one of the following 14 symptoms minimally
- 4 after weeks of receiving a positive test result for SARS-CoV-2", based on the Centers for Disease
- 208 Control (CDC) their staging at the time: chest pain, concentration problems, cough, fatigue, headache,
- 209 heart palpitations, loss of appetite, reduced muscle strength, loss of sense of smell, loss of sense of taste,
- 210 muscle ache, reduced physical endurance, shortness of breath, and sleeping problems [5,17].

Our second objective was to develop a pragmatic risk score formula using variables that could be easily obtained by a GP in clinical practice on Bonaire. We selected predictors with the perspective of the data collection being feasible in GPs' everyday practice. Hence, these included factors and data that GPs register in the patient file with regard to the COVID-19 infection consultation, factors that are generally available in the GP's electronic patient database, or factors which are easily accessible upon verbal inquiry with the patient.

Demographic factors included age, sex (male/female), and education level. We categorized age into groups 0-19 years, 20-39 years, 40-59 years, and 60+ years old. Education level was categorized as low, moderate or high [21]. Low education indicated no education, primary level education, lower vocational and lower secondary education; moderate indicated higher secondary education, and high indicated university level post-secondary education. Health-related factors included pre-pandemic smoking (yes/no), alcohol use (yes/no), BMI, and comorbidities. For BMI, we removed one outlier (>70), and categorized remaining values into underweight (<18), normal (>18,<25), overweight (>25-<30), obese

224 ( $\geq$ 30-<35) and morbidly obese ( $\geq$ 35).

Comorbidity was categorized as the presence of at least one underlying disease (yes/no). Comorbidities included specific underlying diseases with a diagnosis, such as diabetes, cardiovascular disease, depression, neurocognitive disorders, stroke, and more. COVID-19 related factors included acute phase GP visit, hospitalized for COVID-19 during the acute phase (not stratified by ICU or general care) and number of symptoms present during acute phase. Definitions of variables considered in the analyses are further specified in **Supplementary Table 1**.

#### 231 Statistical methods

- First, descriptive statistics and univariate analyses were conducted comparing PCC to non-PCC cases
- and comparing the COVID-19 cohort to community controls using Fisher's exact test or Wilcoxon test
- where appropriate. We considered a p-value <0.05 as statistically significant. All analyses were carried
- 235 out in R version 4.1.3 (R Foundation for Statistical Computing).

## 236 Sparse and rich models

- 237 Thereafter, we developed two sets of models using variables that could be easily obtained by a GP in
- 238 clinical practice on Bonaire. The first set is sparse and includes patient characteristics that, based on
- discussions with a local GP, are easily attainable from a GP practice patient file. The variables
- 240 included in this model are age, sex, presence of one or more comorbidities, hospitalization for
- 241 COVID-19 during the acute phase and GP visit during the acute phase of a SARS-CoV-2 infection.
- 242 The second set is richer and includes additional variables not routinely registered in GP patient files
- but which should be obtainable with relative ease upon a patient's visit or verbal inquiry by telephone:
- BMI, lifestyle factors (such as whether a patient smokes or uses alcohol) and the number of symptoms

experienced during the acute phase of their SARS-CoV-2 infection. Because having been hospitalized

- for acute COVID-19 was shown to be a strong predictor of PCC during explorative analyses, within
- each set we built one model for the full patient sample (hospitalized and non-hospitalized during acute

248 COVID-19) and one model for non-hospitalized patients only. Thus, four models were built:

- 249 Models based on the full patient sample including both hospitalized and non-hospitalized patients 250 (n=390) included the following variables:
- Model 1a (sparse model): age, sex, presence of one or more comorbidities, acute phase GP visit,
   and acute phase hospitalization;
- Model 2a (rich model): age, sex, presence of one or more comorbidities, BMI, smoking status,
   alcohol use, education level, number of symptoms experienced during acute phase, acute phase
   GP visit, and acute phase hospitalization.
- 256 Models based on the non-hospitalized patient sample (n=362) included the following variables:
- 257 Model 1b (sparse model): age, sex, presence of one or more comorbidities, and acute phase GP
   258 visit;
- Model 2b (rich model): age, sex, presence of one or more comorbidities, BMI, smoking, alcohol
   use, education level, number of symptoms experienced during acute phase, and acute phase GP
   visit.

#### 262 Development of risk score formula

Multivariate logistic regression models were fit using PCC status as the outcome variable. Regression 263 264 coefficients from fitted models were then multiplied by 10 and rounded to the nearest integer to derive 265 a risk score formula (Supplementary Tables 2 and 3). The risk score formula was then applied to 266 calculate a risk score for each COVID-19 patient. The discriminatory performance of the risk score was 267 then assessed by plotting the receiver operating curve (ROC) and calculating the area under the curve 268 (AUC) and its 95% CI using 2000 stratified bootstrap replicates implemented in the pROC package in 269 R [22]. Discriminatory performance relates to how well the risk score can distinguish between PCC 270 patients and non-PCC cases. We then assessed the risk score formula's calibration and performed 271 internal validation using the optimism bootstrapping implemented in the rms R package 272 (Supplementary Figure 2) [23]. Using the sensitivity and specificity values for each risk score cut-off 273 in the ROC curves, we then calculated the positive predictive value (PPV) and negative predictive value (NPV) of our risk score formula for each risk score cut-off. The PPV and NPV were calculated with the 274 275 formulas below using this study's PCC prevalence estimate of 39%:

276 
$$PPV = \frac{sensitivity * prevalence}{(sensitivity * prevalence) + ((1 - specificty) * (1 - prevalence))} * 100$$

277

278 
$$NPV = \frac{specificity * (1 - prevalence)}{(1 - sensitivity) * prevalence + (specificity * (1 - prevalence))} * 100$$

279

#### 280 Missing data

Prior to fitting multivariate logistic regression models, we examined the extent of missing data for all
variables we aimed to include. We opted for a complete case-analysis, thereby excluding n=24 (5.8%)
cases from the COVID-19 cohort. Of excluded cases, we confirmed they did not have disproportional
baseline patient characteristics.

#### 285 Sensitivity analysis

We investigated whether an intermediate risk scoring tool could attain a similar AUC as our rich risk scoring tool. This intermediate scoring tool uses fewer patient characteristics than our rich risk scoring tool, but more than our sparse risk scoring tool. The variables included were: age, sex, presence of one or more comorbidities, GP visit during the acute phase, alcohol use, smoking, and BMI (**Supplementary** 

**Tables 4 and 5**).

#### 291 **RESULTS**

#### 292 **Participants**

All cases recorded in the national case registry 'HP Zone' by 1 October 2021 (n=2,036) were assessed

for eligibility. Based on the inclusion criteria, 1,789 individuals were eligible for study participation.

Of the excluded persons,133 individuals were non-residents, 95 were asymptomatic and 19 had passed

away at the time of inclusion. Of the eligible individuals, 357 were not reached after three attempts, 76

did not have time to participate, 66 did not want to participate, 47 had switched phone numbers and

were not reachable anymore, 15 did not see a value in participating, four did not understand or trust

the interview procedure, and 73 had another, unspecified, reason not to participate.

- 300 Of another 545 individuals, reason of non-participation was not recorded and 103 did not give
- 301 informed consent. Of interviewed individuals, 8 did not finish the interview, three changed their mind
- about participating, one did not want to clarify whether they had had COVID-19, and of two, date of
- birth was not registered. In total, 489 respondents were included in the study (Figure 1), of whom 414
- 304 were lab-confirmed SARS-CoV-2 positive cases and 75 had a self-reported SARS-CoV-2 negative
- status (median age 43, IQR 26).

306

# Fig. 1 STROBE flowchart describing participant selection for the study examining prevalence and predictive factors of PCC on Bonaire, Caribbean Netherlands

#### 309

#### 310



#### 311

312 Out of a total of 2,036 SARS-CoV-2 positive cases detected until October 1<sup>st</sup>, 2021, 133 cases were 313 not eligible for inclusion because they were not a permanent resident of Bonaire, 95 because they were 314 asymptomatic, and 19 were not eligible due to non-survival by 1 October 2021. Thus, there were 1,789 315 cases confirmed eligible for inclusion. Of these, 57 cases had been hospitalized during the acute phase of infection. A total of 1,195 eligible participants were called during the interview period (67%), of 316 317 whom 986 were reached (83%). The final sample consisted of 503 participants who had given 318 informed consent (52%). Of these, 14 were excluded as they could not be categorized into one of the 319 subgroups, for reasons such as missing date of onset or date of birth or choosing to stop participation 320 during the interview. This flowchart has also been published in the sub-study by Berry et al. (2023) 321 ['manuscript in preparation']

#### 322 **Baseline characteristics**

- 323 160 cases (39%) fit the case definition of PCC (median age 43, IQR 21). At the time of interview, 107
- patients had recovered from PCC. Of recovered patients, 42 (39%) recovered within 2 months after
- disease onset, 27 (25%) recovered within 3 months, 16 (15%) within 4 months and 21 (20%) patients
- had not recovered after 4 months of disease onset. Time to recovery was unknown for 1 patient. 53
- 327 patients were unrecovered at the time of interview and had a median duration of illness of 250 days
- 328 (IQR 34).
- In all three groups, there were more female participants than males (**Table 1**). PCC prevalence was
- higher among females (38%) than males (25%), highest in the age group 40-59 years old (40%),
- highest among morbidly obese patients (31%), and higher in cases hospitalized during the acute phase
- of infection (80%) as compared to the non-hospitalized group (35%).
- 333 Significant differences regarding sex, BMI, and age were observed in PCC patients compared to non-
- PCC cases, but these characteristics did not differ between the overall COVID-19 positive group (PCC
- and non-PCC cases combined) and community controls. This implies that our sampling method for
- 336 community controls, aimed at a comparable distribution of main baseline characteristics between
- 337 COVID-19 patients and community controls, was effective.
- **Table 1** Baseline demographics and univariate analyses to assess between group differences

	PCC patients (n=160)	Non-PCC cases (n=254)	Overall positive cohort (n=414)	Community controls (n=75)	P value (PCC vs. non-PCC cases)	P value (Community controls vs. overall positive cohort)
<b>Character</b>	<u>istics</u>					
Median	43 (21)	39 (23)	40 (23)	43 (26)	<0.007 <sup>A</sup>	0.09 <sup>A</sup>
age (IQR)						
Age group	S				<0.003 <sup>B</sup>	0.14 <sup>B</sup>
0-19	6 (4%)	36 (14%)	42 (10%)	3 (4%)		
20-39	61 (38%)	98 (39%)	159 (38%)	28 (37%)		
40-59	64 (40 %)	85 (34%)	149 (36%)	25 (33%)		
60+	29 (18%)	34 (13%)	63 (15%)	19 (25%)		
Unknow n	0	1 (0%)	1 (0%)	0		
Sex					<0.001 <sup>B</sup>	0.47 <sup>B</sup>
Male	46 (29%)	115 (45%)	161 (39%)	25 (33%)		
Female	114 (71%)	138 (54%)	252 (61%)	50 (67%)		
Non- binary	0	1 (0%)	1 (0%)	0		

Education	level				0.15 <sup>B</sup>	0.78 <sup>B</sup>
Low	119	208 (82%)	327 (79%)	57 (76%)		I
	(74%)					
Moderate	23	29 (11%)	52 (13%)	12 (16%)		
	(14%)	14(50)	21 (00())			
High	(11%)	14 (6%)	31 (8%)	6 (8%)		
Unknow	1 (1%)	3 (1%)	4 (1%)	0		
n						
Pre-pande	emic factor	S				
Median	30.2	28.1	29.0	28.7 (8.32)	<0.001 <sup>A</sup>	0.78 <sup>A</sup>
BMI	(11.3)	(8.71)	(9.38)			
(IQR)						
BMI categ	gory	1	1	1	<0.001 <sup>B</sup>	0.92 <sup>B</sup>
Underwe ight	2 (13%)	4 (2%)	6 (1%)	1 (1%)		
Normal	32	80 (32%)	112 (27%)	19 (25%)		
	(20%)		111 (2004)			
Overwei ght	41 (26%)	73 (29%)	114 (28%)	22 (29%)		
Obese	36 (23%)	53 (21%)	89 (21%)	19 (25%)		
Morbidly	49	42 (17%)	91 (22%)	1 (1%)		
obese	(31%)					
Unknow	0	2 (1%)	2 (0%)	0		
Comorbid	lities		1		0.05 <sup>B</sup>	0.40 <sup>B</sup>
Yes, one	33	33 (13.0	66 (16%)	15 (0%)		0.10
or more	(21%)	%)				
No	127	221	348 (84%)	60 (80%)		
	(79%)	(87.0%)				
Smoking					0.45 <sup>B</sup>	0.66 <sup>B</sup>
Yes	18 (11%)	36 (14%)	54 (13%)	14 (19%)		
No	142	215 (85%)	357 (86%)	61 (81%)		
	(89%)					
Unknow	0	3 (1%)	3 (1%)	0		
	 Se				0.29 <sup>B</sup>	0 73 <sup>B</sup>
Yes	109	158 (62%)	267 (65%)	44 (59%)	0.27	0.75
	(68%)		207 (0570)			
No	51 (32%)	94 (37%)	145 (35%)	30 (40%)		
Unknow n	0	2 (1%)	2 (0.5%)	1 (1%)		
Factors de	iring scute					
Median	10(5)	5 (7)	7 (8)	_	<0.001 <sup>A</sup>	-
number	10(3)					
of						
sympto						
ms						

		1	1	1		
present						
					-	
GP visit					$0.02^{B}$	-
Yes	14 (9%)	8 (3%)	22 (5%)	-		
No	146	233 (92%)	379 (92%)	-		
	(91%)					
Unknow	0	13 (5%)	13 (3%)	-		
n						
Hospitaliz	ation				<0.001 <sup>A</sup>	-
Yes	24	6 (2%)	30 (7%)	-		
	(15%)					
No	136	235 (93%)	371 (90%)	-		
	(85%)					
Unknow	0	13 (5%)	13 (3%)	-		
n						

339 <sup>A</sup> Wilcoxon test. <sup>B</sup> Fisher's exact test.

Post COVID-19 Condition (PCC); Inter Quartile Range (IQR); Body Mass Index (BMI); General

341 Practitioner (GP).

## 342 Symptomatology

- 343 Among the SARS-CoV-2 positive cohort, presence of shortness of breath (OR=2.27 [1.07-4.94]) or
- reduced physical endurance (OR=3.34 [1.13-11.09]) prior to infection were significantly associated
- 345 with PCC. All symptoms except chest pain were significantly more often experienced during the acute
- 346 phase by patients that developed PCC than patients who did not (**Supplementary Table 6**). Among
- 347 PCC patients, the most prevalent acute symptoms included fatigue (85%), reduced physical endurance
- 348 (83%), headache (78%), and reduced muscle strength (76%) (**Supplementary Table 7**). Of non-PCC
- cases, 48% reported fatigue, 46% worsened physical endurance, 61% headache, and 39% reduced
- 350 muscle strength in the acute phase.
- In the post-acute phase, fatigue (67%) and reduced physical endurance (66%) were the most persisting
- 352 symptoms. Persisting chest pain (37%) and sleeping problems (46%) were more prevalent among
- 353 female PCC patients (vs. 22% and 28% among male patients, respectively). Common symptoms
- among patients over 60 years old included reduced physical endurance (79%), fatigue (76%) and loss
- of appetite (76%). Concentration problems, reduced physical endurance, shortness of breath, and
- 356 reduced muscle strength were predominant among patients who had been hospitalized in the acute
- 357 phase, as opposed to patients who had not been hospitalized (Supplementary Table 7). There was no
- 358 significant association between presence of one or more comorbidities, sex, age group, or
- 359 hospitalization during the acute phase and each of the fourteen symptoms in the post-acute phase
- 360 (Supplementary Table 7).

#### 361 PCC screening based on a simple risk score

- 362 In total, 390 respondents were included in risk score analyses of which 40% (n =156) were PCC
- patients. The distributions of the risk scores are shown in **Figure 2** and the risk score formulas used to
- 364 calculate a risk score per patient in **Supplementary Table 3**. Baseline characteristics for PCC patients

- and non-PCC cases included are shown in **Supplementary Table 8**. The risk score ranges calculated
- using the sparse risk score formulas are narrower compared to the risk score ranges calculated from
- the rich risk score formulas (**Figure 2**). The sparse risk scoring tool based on the full patient sample
- had an Area Under the Curve (AUC) of 0.68 (bootstrapped 95 CI% 0.63 0.74), whereas the sparse
- risk scoring tool based on the non-hospitalized patient sample had an AUC of 0.65 (bootstrapped 95%
- CI 0.59 0.71). The rich risk scoring tool based on the full patient sample had an AUC of 0.79 (95)
- CI% 0.74 0.83) and the rich risk scoring tool based on the non-hospitalized patient sample had an
- AUC of 0.77 (95CI% 0.72 -0.82). ROC curves are shown in **Supplementary Figure 3**. The graphs in
- **Figure 3** can be used to assess the trade-off between time and resource investment and identifying a
- 374 greater number of people at risk of developing PCC. Generally, a higher risk score cut-off results in a
- higher PPV and lower NPV.

376

## 377 Fig. 2 PCC risk score distributions



Histogram showing the distribution of PCC risk scores calculated with risk score formulas. (A) Risk
score distribution using the sparse risk score formula based on the full patient sample. (B) Risk score
distribution using the sparse risk score formula on non-hospitalized sample. (C) Risk score distribution
using the rich risk score formula based on the full patient sample. (D) Risk score distribution using the
rich risk score formula based on non-hospitalized sample.

390



## **Fig. 3** Positive and negative predictive values per risk score cut-off

392

393 Positive predictive value (PPV) and negative predictive values (NPV) per risk score cut-off. (A)

394 Sparse risk scoring tool based on full patient sample. (B) Sparse risk scoring tool based on non-

hospitalized sample. (C) Rich risk scoring tool based on full patient sample. (D) Rich risk scoring toolbased on non-hospitalized sample.

397

## 398 Worked example of using risk score for PCC screening

We provide worked examples for two scenarios in **Table 2**, using the graphs in **Figure 3**. The first scenario reflects a low-resource setting, where a high PPV and high risk score cut-off are desirable given the limited number of people that would have to be contacted. All those who would be contacted in this scenario would have a high probability of being true PCC patients. A disadvantage, however, is that in this scenario many other true PCC patients may miss out on being contacted. Contrarily, in the second,

high resource scenario, a high NPV and low risk score cut-off may be desirable. Here, many patients
would be contacted which would increase the number of false positives; however most true PCC patients

- 406 would be reached.
- 407 To illustrate the above points, we provide worked examples based on the rich risk scoring tool based on
- the full sample and the rich risk scoring tool based on the non-hospitalized sample for a low- and high-
- 409 resource setting. Taking the low-resource setting as an example, our aim would be to identify as many
- 410 true PCC patients whilst minimizing capacity going towards contacting efforts. Therefore, a high risk
- 411 score cut-off and PPV is desirable; yet care must be taken not to choose a risk score that is at the tail
- 412 end of the distribution, given few people will have such a score (Figure 2). Based on Figure 3, we chose
- a risk score of 40 with a PPV around 70%. Applying the risk scoring tool to our data, we found that 92
- 414 patients had a risk score of 40 or greater, of whom 66 (72%) were true PCC patients, yet 90 other true
- 415 PCC patients would be missed as they would not be contacted.

416 **Table 2** Number of patients who would be contacted (Call +) who truly have or do not have

417 PCC for different risk score cut-offs

#### 418 A

## A. Low-resource setting

	PCC +	PCC -	Total	
Hospitalized and non-ho	spitalized PCC patients <sup>a</sup>			
Call +	66	26	92	
Call -	90	208	298	
	156	234	390	
Non-hospitalized PCC patients <sup>b</sup>				
Call +	64	36	100	
Call -	70	192	262	
	134	228	362	

419 <sup>a</sup>Risk score cut-off 40, using our rich risk scoring formula based on full patient sample.

<sup>b</sup> Risk score cut-off 35, using our rich risk scoring formula based on non-hospitalized sample.

## 421 **B.** High resource setting

	PCC +	PCC -	Total
Hospitalized and non-ho	spitalized PCC patients <sup>a</sup>		
Call +	151	183	334
Call -	5	51	56
	156	234	390
Non-hospitalized PCC p	atients <sup>b</sup>		
Call +	124	119	243
Call -	70	109	119
	134	228	362

422 <sup>a</sup> Risk score cut-off 35, using our rich risk scoring formula based on full patient sample.

<sup>b</sup> Risk score cut-off 20, using our rich risk scoring formula based on non-hospitalized sample.

#### 424 Sensitivity analysis

- 425 Our intermediate risk scoring tool for the full patient sample had an AUC of 0.71 (95% CI, 0.65 –
- 426 0.76) and the AUC was 0.67 (95% CI, 0.61-0.73) for the non-hospitalized patient sample
- 427 (Supplementary Table 5).

## 428 **DISCUSSION**

- 429 PCC is a debilitating condition and evidence regarding prevalence, symptomatology, and risk
- 430 screening tools are lacking in the Caribbean context. In our study, 39% of COVID-19 cases on
- Bonaire experienced at least one persisting symptom for at least four weeks after disease onset. Most
- 432 common persisting symptoms included fatigue (67%) and reduced physical endurance (66%).
- Additionally, we describe proof-of-concept risk scoring tools using easily obtainable patient
- 434 characteristics with good discriminatory power, which, after external validation in other study
- populations, could aid in the timely identification of those at increased risk of PCC. This is important
- because long-COVID rehabilitation care on Bonaire needs to be applied for within a specified time
- 437 frame in order to be eligible for health insurance coverage [16].

## 438 **Prevalence**

- 439 Symptom attribution to SARS-CoV-2 infection has shown to be challenging and there is substantial
- heterogeneity in prevalence estimates both within and between studies. This is caused by differences
- in case definition (such as duration of illness and type of symptoms) and differences in region,
- 442 characteristics, and hospitalization status of the study populations [2, 6, 24]. For example, our estimate
- of 39% of symptomatic acute COVID-19 cases having symptoms for more than 4 weeks is in line with
- 444 a recent global PCC pooled prevalence estimate of 43% (95% CI, 39-46) [2], however, it is lower than
- an estimate from a prospective cohort study in the European Netherlands of 49% of cases reporting at
- least one symptom three months after SARS-CoV-2 infection [6].
- 447 Our PCC case definition is based on the (CDC) working definition at the time of interview, using a
- 448 cutoff of at least four weeks after disease onset [17]. The WHO case definition at the time of writing,
- 449 on the other hand, indicates that a symptom should persist for at least 12 weeks after infection, of
- 450 which at least 8 weeks cannot be explained by an alternative diagnosis [25]. This difference in follow-
- 451 up time is important as its been shown to affect PCC prevalence estimates. Results of a meta-analysis
- 452 analyzing global PCC estimates by Chen et al. (2022) reveal that PCC prevalence was 37 % when
- 453 using a 30 day follow-up definition (95% CI, 26-49%), which decreased to 25% (95% CI, 15-38%)
- 454 when a 60 day follow-up definition was used [2]. Surprisingly, prevalence across studies increased
- 455 again to 32% (95% CI, 14- 57%) and 49% (95% CI, 40-59%) using follow-up definitions of 90 and
- 456 120 days; possibly due to oversampling of hospitalization patients in the study populations of studies
- 457 with longer follow up [2]. Using the WHO case definition, we observed a PCC prevalence 23% among
- 458 our sample.

- 459 Consistent with other studies, we found that fatigue (67%) was the most common PCC symptom,
- followed by reduced physical endurance (66%) [26]. Among a sample of European Dutch and Belgian
- 461 patients, Goertz et al. (2020) found fatigue (87%) and shortness of breath (71%) were most prevalent
- 462 PCC symptoms [27]. Van der Maaden et al. (2023) found a significantly higher prevalence of fatigue
- 463 (31.1%), dyspnea (16.4%), concentration problems (15.0%) and several other symptoms among cases
- 464 from the European Netherlands as compared to control groups [6].

#### 465 **Risk scoring tool**

- 466 Besides gaining insight into PCC prevalence on Bonaire, practical and easy-to-use risk scoring tools
- 467 for public and primary care are needed in low resource-settings to screen and identify persons that are
- 468 at risk of developing PCC. Few PCC prediction tools exist and the ones that do, do not necessarily
- have practicality of use in mind making them less usable for low-resource settings nor are they
- 470 applied to Caribbean populations. Our sparse risk scoring tool, using patient characteristics that are
- 471 easily obtainable by GPs in practice (i.e. age, sex, presence of one or more comorbidities,
- 472 hospitalization or GP visit for acute COVID-19); resulted in moderate discriminative power for the
- 473 prediction of PCC. Adding smoking, alcohol use, BMI, education level, and number of symptoms in
- the acute phase improved the discriminative power considerably in the full patient sample
- 475 (hospitalized plus non-hospitalized) as well as for the non-hospitalized patient sample.
- 476 Our results highlight the importance of obtaining certain patient characteristics for designing risk scoring 477 tools either at intake or upon verbal inquiry with the patient. The moderate discriminatory performance 478 of our sparse risk scoring tools - suggest that solely using baseline characteristic is not optimal in 479 identifying patients at risk for PCC. Our rich risk scoring tools, on the other hand, showed a marked 480 increase in discriminatory performance allowing for better delineation of PCC patients. Importantly, our 481 risk scoring tools excluding hospitalized patients still obtained a good predictive performance aiding in 482 the identification of PCC patients, which in absolute numbers is the largest patient population at risk for 483 PPC. Sensitivity analysis showed a moderate performance of our intermediate risk scoring tool when 484 including hospitalized patients. However, when excluding hospitalized patients, its discriminatory 485 performance was poor-to-moderate and similar to our sparse risk scoring tool. This indicates that 486 education level, and in particular the number of symptoms during the acute phase, are important 487 predictors for PCC risk in the non-hospitalized population.
- Although our rich risk scoring tools had a better discriminatory performance, calibration plots also show
  they overpredict PCC risk at higher predicted probabilities and underpredict at lower predicted
  probabilities (Supplementary Figure 2). This behavior is not necessarily problematic if risk scores are
  used as a PCC screening tool. In practice overoptimistic PCC risk prediction will result in a greater
- 492 number of false positives. Although more false positives in this case would result in an increased use of

493 capacity to contact patients, there would be negligible negative consequences for patients, as they could494 simply inform their GP whether they are experiencing persisting symptoms or not.

#### 495 Strengths & Limitations

496 We designed the first retrospective cohort study estimating the prevalence and characteristics for PCC 497 in the Dutch Caribbean context and devised a simple risk scoring formula to estimate PCC risk. Our 498 study adds valuable insight into PCC prevalence for the Caribbean region, which has been 499 underrepresented in PCC research [15]. A major strength of our study was that we included a negative 500 control group, age-sex matched to the COVID-19 cases, to assess baseline health status, and only few 501 studies have done this thus far [24]. We found no significant difference in baseline demographic 502 characteristics between the COVID-19 cohort and community controls, allowing an unbiased 503 comparison of pre-existing health.

504 Contrary to most studies [24], we collected data on symptoms present before the SARS-CoV-2 infection 505 for PCC patients, non-PCC cases, and community controls. Prior to the pandemic, symptoms were 506 experienced to a similar or slightly higher degree by PCC patients than community controls, though we 507 had limited statistical power to assess the significance of these differences. However, considering the 508 vastly higher prevalence of symptoms post COVID-19 among PCC patients compared to their pre-509 pandemic experience and compared to the community controls, it is not likely that all PCC 510 symptomatology can be explained as previously existing symptoms now being labeled as post-acute 511 symptoms.

512 We did find that COVID-19 patients who reported already experiencing shortness of breath (OR=2.27 513 [1.07-4.94]) and reduced physical endurance (OR=3.34 [1.13-11.09]) prior to infection were more likely 514 to suffer from post-acute symptoms than COVID-19 patients without these two pre-existing symptoms. 515 A recent study using the European Netherlands Lifelines cohort data matched SARS-CoV-2 positive 516 cases with a control group of SARS-CoV-2 negative participants and found that one in eight COVID-517 19 cases had persistent symptoms for 90-150 days after their acute COVID19 infection that could be 518 attributed to their infection [2]. Our inclusive sampling strategy, i.e., inviting all residents on Bonaire 519 who had received a SARS-CoV-2 positive test result before 1 October 2021 and experienced a 520 symptomatic infection to participate in the study, supports the generalizability of our findings to the 521 COVID-19 patient population on Bonaire.

As community controls were included based on self-reported SARS-CoV-2 negative status, PCC prevalence may be affected if these respondents were instead untested, SARS-CoV-2 positive cases. We opted to use patient reported data rather than using validated instruments for patient characteristics, previously registered patient data, or diagnostic tools for underlying disease, which would require more capacity and resources to obtain. Using self-reported data on presence of these symptoms may have led to information bias, though we believed our approach would result in more data considering the low-

- resource setting of our study. We did not expect potential information bias to impact our results, as we
- assumed this would not differ across subgroups. It is important to note that our risk score formula has
- 530 not been externally validated. Our risk score formulas should therefore be interpreted as a proof-of-
- 531 concept, and external validation would be needed before they can be utilized for PCC screening in
- 532 general practice or public health settings.

## 533 Implications for research, clinicians and policymakers

- 534 Our study adds valuable insight into PCC prevalence for the Caribbean region, which has been an
- underrepresented region for PCC research. Since the start of the pandemic, Bonaire reported 9,822
- 536 SARS-CoV-2 cases, of whom 98.5% concerned non-hospitalized cases with mild or asymptomatic
- infections (up to 8 January 2023) [9]. Applying our PCC prevalence of 39%, we expect that a
- substantial group of (former) COVID-19 patients may be experiencing persisting symptoms without
- seeking care at their GP, leaving the condition undiagnosed or with vast diagnostic delay among the at
- risk population [28]. GPs will require adequate tools to identify at risk patients, preferably using easy
- to use screening tools. Here, we highlight the added benefit of obtaining extra patient characteristics
- 542 either at intake or upon verbal inquiry for improved PCC screening and stress the need for further
- research into external validation of risk scoring formulas.

## 544 CONCLUSION

- 545 We estimated a PCC prevalence of 39% on Bonaire four weeks after disease onset. Moreover, easily
- 546 obtainable patient characteristics can be used to build a risk scoring tool with moderate-to-good
- 547 discriminatory power to identify those with PCC. If used for PCC screening, our risk scoring tool
- 548 could aid public health in low-resource settings, however it needs to be externally validated first.

## 549 **REFERENCES**

550	1.	World Health Organization. WHO coronavirus (COVID-19) dashboard [online]. 2023.
551		Available from: https://covid19.who.int/ (accessed 12 January 2023).
552	2.	Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease
553		2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J
554		Infect Dis 2022;226:1593-1607; https://doi.org/10.1093/infdis/jiac136
555	3.	Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of
556		long COVID: a review. J R Soc Med 2021;114:428-442;
557		https://doi.org/10.1177/01410768211032850
558	4.	Banda JM., Adderley N, Ahmed W, et al. Characterization of long-term patient-reported
559		symptoms of COVID-19: An analysis of social media data. MedRxiv 2021.07.13.21260449
560		[Preprint]. 2021; https://doi.org/10.1101/2021.07.13.21260449
561	5.	Pergolizzi, JV, LeQuang JA, Magnusson P, et al. It's not over till it's over: a narrative review
562		of Long COVID. Signa Vitae 2021;17:21-30; https://doi.org/10.22514/sv.2021.067
563	6.	van der Maaden T, Mutubuki EN, de Bruijn S, et al. Prevalence and Severity of Symptoms 3
564		Months After Infection With SARS-CoV-2 Compared to Test-Negative and Population
565		Controls in the Netherlands. J Infect Dis. 2023;227(9):1059-1067;
566		https://doi.org/10.1093/infdis/jiac474
567	7.	Bosman L, van den Hoek R, van Waarden W, et al. Het Post-COVID-syndroom: hoe
568		definiëren we het en hoe vaak komt het voor? [online]. 2022. Available from:
569		https://www.nivel.nl/nl/publicatie/het-post-covid-syndroom-hoe-definieren-we-het-en-hoe-
570		vaak-komt-het-voor (accessed 16 August 2022).
571	8.	Central Bureau of Statistics (CBS). Caribbean Netherlands; population, births, deaths,
572		migration. 2022. Available from: https://www.cbs.nl/en-
573		gb/figures/detail/83774ENG?q=bonair (accessed 16 August 2022).
574	9.	National Institute for Public Health and the Environment. COVID-19 weekly epidemiological
575		update for the Caribbean part of the Kingdom [online]. 2021. https://www.rivm.nl/en/novel-
576		coronavirus-covid-19/current-information/covid-19-monthly-epidemiological-update-for-
577		caribbean-part-of-kingdom (accessed 15 October 2021).
578	10.	United Nations Office for Disaster Risk Reduction. Regional Office for the Americas and the
579		Caribbean Economic Commission for Latin America and the Caribbean. The coronavirus
580		disease (covid-19) pandemic - an opportunity for a systemic approach to disaster risk for the
581		Caribbean [online]. 2021. https://www.undrr.org/publication/undrr-eclac-report-coronavirus-
582		disease-covid-19-pandemic-opportunity-systemic-approach (accessed 16 August 2022).

583	11.	Openbaar Lichaam Bonaire. Directie Samenleving en Zorg. Afdeling Publieke Gezondheid.
584		Publieke Gezondheid op Bonaire 2020-2023. Een blik op de gezondheidssituatie van de
585		Bonairiaanse bevolking en de weg vooruit naar een gezondere toekomst. Bonaire: Openbaar
586		Lichaam Bonaire; 3 October 2022. 28.
587	12.	Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization,
588		and death by Race/Ethnicity. 2022. Available from: https://www.cdc.gov/coronavirus/2019-
589		ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html
590		(accessed 12 January 2023).
591	13.	Kaiser Family Foundation. Covid-19 cases and deaths by Race/ethnicity: Current data and
592		changes over time. [place unknown], [publisher unknown]. 2023. Available from: from
593		https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-cases-and-deaths-by-race-
594		ethnicity-current-data-and-changes-over-time/ (accessed 12 January 2023).
595	14.	Pressley A, Beyer D. Congressional Letter on Long Covid. 25 January 2022. Congress of the
596		United States. House of Representatives. Available from:
597		$\underline{https://pressley.house.gov/sites/pressley.house.gov/files/Pressley%20Beyer%20Congressional}$
598		%20Letter%20on%20Long%20COVID.pdf (accessed 13 January 2023).
599	15.	Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic
600		review. BMJ Glob Health 2021;6:e005427; https://doi.org/10.1136/bmjgh-2021-005427
601	16.	Regeling Aanspraken Zorgverzekering Bes wetten.nl - Regeling - Regeling aanspraken
602		zorgverzekering BES - BWBR0029442. [place unknown]. Available from:
603		https://wetten.overheid.nl/BWBR0029442/2023-01-20 (accessed 16 April 2023).
604	17.	Department of Health and Human Services. USA government. What is long COVID? Long
605		COVID terms and definitions development explained. 2023. Available from
606		https://www.covid.gov/longcovid/definitions (accessed 12 January 2023).
607	18.	Digitale Checklisten. Grip op ieder proces. 2023. Available from: https://tempobonaire.com/nl
608		(accessed 16 January 2023).
609	19.	Tempo Flexible Manpower. Let's shape the future of staffing. [place unknown], [publisher
610		unknown]. 2023. Available from: https://digitalechecklisten.nl/ (accessed 16 January 2023).
611	20.	The Central Committee on Research Involving Human Subjects. Home page. [place
612		unknown], [publisher unknown]. 2023. Available from: https://english.ccmo.nl/ (accessed 12
613		January 2023).
614	21.	Mutubuki EN, van der Maaden T, Leung KY, et al. Prevalence and determinants of persistent
615		symptoms after infection with SARS-CoV-2: protocol for an observational cohort study
616		(LongCOVID-study). BMJ Open 2022;12:e062439; https://doi.org/10.1136/bmjopen-2022-
617		062439

618	22.	Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze
619		and compare ROC curves. BMC Bioinformatics 2011;12:77; https://doi.org/10.1186/1471-
620		2105-12-77
621	23.	Harrell FE. Regression modeling strategies: With Applications to Linear Models, Logistic and
622		Ordinal Regression, and Survival Analysis. New York, USA: Springer 2015; 11-105.
623	24.	Brightling CE, Evans RA. Long COVID: which symptoms can be attributed to SARS-CoV-2
624		infection? Lancet 2022;400:411-413; https://doi.org/10.1016/S0140-6736(22)01385-X
625	25.	World Health Organization. Post covid-19 condition (long covid). [place unknown], [publisher
626		unknown]. 2023. Available from https://www.who.int/europe/news-room/fact-
627		sheets/item/post-covid-19-condition (accessed 12 January 2023).
628	26.	Ballering AV, van Zon SKR, Olde Hartman TC, et al. Lifelines Corona Research Initiative.
629		Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort
630		study. Lancet 2022;400:452-461; https://doi.org/10.1016/S0140-6736(22)01214-4
631	27.	Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a
632		SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020;6:00542-2020;
633		https://doi.org/10.1183/23120541.00542-2020
634	28.	Greenhalgh T, Sivan M, Delaney B, et al. Long covid-an update for primary care. BMJ
635		2022;378:e072117; https://doi.org/10.1136/bmj-2022-072117
676		
050		
637		
638		
639		
640		
641		
041		
642		
6.40		
643		
644		
645		
646		

## 647 STATEMENTS & DECLARATIONS

648

## 649 Funding

- 650 "This work was funded by the RIVM department CIb their RAC programme budget: Research budget
- 651 (grant number 0113/2021, August 5th 2021)".

### 652 Competing Interests

The authors have no conflict of interest to declare that are relevant to the content of this article.

## 654 Author Contributions

- LJ secured funding for the performance of the study; LJ, DB, GM, IT and EG contributed to the study
- 656 conception and design; LJ, GM and IT established data collection procedures; IT was responsible for
- data registry; DB and EG defined the statistical analysis plan; DB, TD, LJ, EG and GM contributed to
- the synthesis of key findings and interpretation of the results; DB performed the primary literature
- search, carried out descriptive and univariate analyses, and took co-lead in drafting and writing of the
- 660 manuscript prior to publication. TD carried out descriptive analyses, quantitative analyses, and took
- 661 co-lead in drafting the manuscript prior to publication; EG, LJ, IT and GM critically reviewed the
- 662 manuscript.

## 663 **Ethics approval**

- The study protocol was sent to the Central Committee on Research Involving Human Subjects
- 665 (CCMO Netherlands), who confirmed on 8 October 2021 that the study did not require ethical
- approval due to its observational design.

#### 667 **Consent to participate**

668 Informed consent was obtained from all individual participants included in the study.

#### 669 **Consent to publish**

670 Not applicable.

671

672	Supplementary	Information for:
-----	---------------	------------------

673

- 674 The prevalence of post COVID-19 condition (PCC) and a simple risk scoring tool for PCC
- 675 screening on Bonaire, Caribbean Netherlands: a retrospective cohort study.
- 676 Danytza SF Berry<sup>1\*</sup>, Thomas Dalhuisen<sup>1\*</sup>, Giramin Marchena<sup>2</sup>, Ivo Tiemessen<sup>3</sup>, Eveline Geubbels<sup>1</sup>
- 677 Loes Jaspers<sup>2</sup>
- 678 \*Joint first authorship.
- 679 Corresponding author: Loes Jaspers, <u>loesjaspers@gmail.com</u>
- 680

## 681 Affiliations:

- <sup>1</sup>National Institute for Public Health and the Environment, Centre for Infectious Disease Control,
- 683 Bilthoven, The Netherlands
- <sup>2</sup> Public Health Department Bonaire, Public Entity of Bonaire, Caribbean Netherlands
- 685 <sup>3</sup> Mobilito, Bonaire, Caribbean Netherlands

686

687	Supplementary content:
-----	------------------------

688	
689	Supplementary Table 1 (S1): Variables used for model building
690	
691 692 693	<b>Supplementary Table 2 (S2):</b> Coefficients from sparse and rich multivariate logistic regression models assessing the risk of PCC in full patient – and non-hospitalized patient samples
694	Supplementary Table 3 (S3): Risk score formulas to calculate the risk of PCC in COVID-19 patients
695	
696 697	<b>Supplementary Table 4 (S4):</b> Coefficients from intermediate multivariate logistic regression models assessing the risk of PCC in full patient (3a)– and non-hospitalized patient (3b) samples
698	
699 700	<b>Supplementary Table 5 (S5):</b> Sensitivity analyses for risk score formulas to calculate the risk of PCC in COVID-19 patients
701	
702 703	<b>Supplementary Table 6 (S6):</b> Prevalence of symptoms (n, %) by subgroup in the pre-pandemic, acute, and post-acute phase
704	
705 706	<b>Supplementary Table 7 (S7):</b> The prevalence of post-acute symptoms across different baseline characteristics of PCC patients (n=160)
707	
708 709	<b>Supplementary Table 8 (S8):</b> Characteristics of SARS-CoV-2 positive cases (n= 390) included in risk scoring tool analyses
710 711 712	<b>Supplementary Figure 1 (SF1):</b> Epiurve and inclusion period for SARS-CoV-2 positive cases on Bonaire, Caribbean Netherlands
713 714 715	<b>Supplementary Figure 2 (SF2):</b> Internal calibration plots for predicting the risk of PCC PCC in COVID-19 patients
716 717	Supplementary Figure 3 (SF3): Receiver Operating Characteristic (ROC) curves for PCC risk scoring tools
718	
719	
720	

## 721 Supplementary Table 1 (S1): Variables used for model building

Variable	Туре	Description
Age	Categorical	Age in years. Categories are:
		0-19 years, 20-39 years, 40-59 years, and 60+ years old
Sex	Binary	Male, female.
Education level	Categorical	Categories are:
		Low level education = no education, primary level
		education, lower vocational & lower secondary
		education, moderate level education = higher secondary
		education, high level education = university level &
		post-secondary education.
BMI	Categorical	BMI (kg/m2), categorized into underweight (<18),
	_	normal ( $\geq$ 18-<25), overweight ( $\geq$ 25-<30), obese ( $\geq$ 30-
		$<35$ ) and morbidly obese ( $\geq 35$ ).
Smoking	Binary	Binary variable indicating whether or not a patient
		smoked cigarettes before the start of the pandemic.
Alcohol use	Binary	Binary variable indicating whether or not a patient used
		alcohol before the start of the pandemic.
Presence of one or more	Binary	Binary variable indicating whether a person suffers from
comorbidities	-	any of the following prior to the start of the pandemic:
		self-reported post-acute respiratory problems (including
		asthma, chronic obstructive pulmonary disorder,
		tuberculosis), post-acute cardiovascular disease,
		diabetes, severe kidney disease (including dialysis or
		kidney transplantation), HIV, severe liver disease, being
		immunocompromised, cancer, depression or anxiety,
		stroke, rheumatism, arthritis, or memory loss due to a
		neurological condition or dementia.
Number of symptoms in	Numerical	Number of symptoms a patient experienced during the
the acute phase		acute phase of their SARS-CoV-2 infection. Symptoms
		include: chest pain, concentration problems, cough,
		fatigue, headache, heart palpitations, loss of appetite,
		reduced muscle strength, loss of sense of smell, loss of
		sense of tase, muscle ache, reduced physical endurance,
		shortness of breath, sleeping problems.
GP visit in the acute phase	Binary	Binary variable indicating whether a patient visited or
		was visited by a GP during the acute phase of their
		SARS-CoV-2 infection.
Hospitalized during the	Binary	Binary variable indicating whether a patient was
acute phase		hospitalized during the acute phase of their SARS-CoV-
		2 infection.

722

## 723 Supplementary Table 2 (S2):

724	Coefficients from sparse and rich multivariate logistic regression models assessing the risk of PCC in full patient - and non-hospitalized patient
725	samples.

																726
	Age			Sex	Presence of	GP	Hospitalized	Alcohol	Smoking	BMI				Education		Number
	(ref ca	at: 0-19	years	(ref:	one or more	visit	during acute	use	(ref:no)	(ref: nor	mal)			(ref: low)		of
	old)			male)	comorbidities	acute	phase (ref:	(ref:	ļ							symptoms
	1				(ref: no)	phase	no)	no)	ļ							acute
	1					(ref:			ļ							phase
	1					no)										-
Model	20-	40-60	60+	Female	Yes	Yes	Yes	Yes	Yes	Under	Over	Obese	Morbidly	Moderate	High	
	39									weight	weight		obese		-	
Sparse	1.17*	1.27**	1.02	0.80***	0.47	0.66***	1.91***	-	-	-	-	-	-	-	-	-
1a	1														1	
Sparse	1.12*	1.16*	0.75	0.72***	0.43	0.90	-	-	-	-	-	-	-	-	-	-
1b	1														1	
Rich	0.30	0.59	0.50	0.46	0.33	0.31	1.17*	0.39	-0.18	0.49	0.33	0.35	0.90**	0.28	0.65	0.19***
2a	1														1	
Rich	0.23	0.46	0.14	0.37	0.23	0.59	-	0.37	-0.06	0.44	0.23	0.37	0.90**	0.31	0.63	0.19***
2b																

727 Note: Reference categories are shown in each column. Significant coefficients are shown in bold; the Asterix refers to three categories: \*p<0.05,

\*\*p<0.01, \*\*\*p<0.001. Models 1a and 2a use the full patient sample (n=390) and Models 1b and 2b use the non-hospitalized patient sample (n=362).

## 730 Supplementary Table 3 (S3):

Risk score formulas to calculate the risk of PCC in COVID-19 patients.

**1a.** Sparse risk score formula based on full patient sample:

733 
$$RiskScore = AgeScore + 8(Ifsex = female) + 5(Ifcomorbidities)$$

734

735

```
= yes) + 7(If GP visit in acute phase = yes) + 19(If hospitalized
= yes)
```

#### 736 Score table:

Age Category	Age Score	
0-19	0	
20-39	12	
40 - 60	13	
60 +	10	

737

<b>10.</b> Sparse fisk score formula based on non-nospitalized sample	738	<b>1b.</b> Sparse risk scor	re formula based or	n non-hospitalized	sample :
---	-----	-----------------------------	---------------------	--------------------	----------

$$Risk \ score \ = \ Age \ Score \ + \ 7(If \ sex \ = \ female) \ + \ 4(If \ comorbidities)$$

740 = 
$$yes$$
) + 9(If GP visit in acute phase =  $yes$ )

#### 741 Score table:

Age Category	Age Score
0-19	0
20 - 39	11
40 - 60	12
60 +	8

742

743 **2a.** Rich risk score formula based on the full patient sample:

$$746 = female) + 2(If comorbidities)$$

747 
$$= yes$$
) + 3(If GP visit in acute phase = yes) + 12(If hospitalized

748 = yes) + 4(If alcohol consumption = yes) - 2(If smoker = yes)

#### 749 Score table:

Age Category	Age Score
0-19	0
20-39	3
40 - 60	6
60 +	5

BMI Category	BMI Score					
Normal	0					
Underweight	5					
Overweight	3					
Obese	4					
Morbidly Obese	9					
Education Category	Education Score					
Low	0					
Moderate	3					
High	7					

**2b.** Rich risk score formula based on non-hospitalized sample:

$$754 = female) + 2(If comorbidities)$$

$$755 = yes) + 6(If GP visit in acute phase)$$

= yes) + 4(If alcohol consumption = yes) - 1(If smoker = yes)

## 757 Score table:

Age Category	Age Score				
0-19	0				
20-39	3				
40 - 60	6				
60 +	5				
BMI Category	BMI Score				
Normal	0				
Underweight	5				
Overweight	3				
Obese	4				
Morbidly Obese	9				
Education Category	Education Score				
Low	0				
Moderate	3				
High	7				

## 759 Supplementary Table 4 (S4):

760 Coefficients from intermediate multivariate logistic regression models assessing the risk of

- 761 PCC in full patient (3a)– and non-hospitalized patient (3b) samples.
- 762

	Age (ref :0	)-19)		Sex (ref: Male)	Comor bidities (ref;no)	Hospital ized (ref: no)	GP visit acute phase (ref: no)	Alcohol use (ref: no)	Smo king (ref: no)	BMI (ref: norm	nal)		
Model	20- 39	40- 60	60+	Femal e	Yes	Yes	Yes	Yes	Yes	Under weight	Over weight	Obese	Morbidly obese
3a	0.86	1.00*	0.8 4	0.74**	0.36	1.92***	0.77	0.31	-0.16	0,35	0.17	0.30	0.80*
3b	0.90	1.06*	1.0 4	0.61*	0.49	-	0.81	0.22	-0.08	0.29	0.27	0.45	0.89**

763 **Note:** Reference categories are shown in each column. Significant coefficients are shown in

bold; the Asterix refers to three categories: \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.

#### **Supplementary Table 5 (S5):**

Sensitivity analyses for risk score formulas to calculate the risk of PCC in COVID-19 patients.

**3a**. Intermediate risk score formula based on full patient sample:

AUC: 0.708 (95CI%, 0.655 - 0.7602)

Risk Score = Age Score + BMI Score + 8(If sex = female)

 $+ 3(If \ comorbidities = yes) + 8(If \ GP \ visit \ in \ acute \ phase = yes)$ 

+ 19(If hospitalized = yes) + 3(If alcohol consumptions

= yes) - 2(If smoker = yes)

Age Category	Age Score
0-19	0
20-39	9
40 - 60	10
60 +	8
BMI Category	BMI Score
Normal	0
Underweight	4
Overweight	2
Obese	3
Morbidly Obese	8

**3b**. Intermediate risk score formula based on non-hospitalized patient sample:

AUC: 0.6742 (95%CI 0.6149 - 0.7291)

## Risk Score = Age Score + BMI Score + 6(If sex = female) + 5(If comorbidities = yes) + 8(If GP visit in acute phase

= yes) + 2(If alcohol consumption = yes) - 1(If smoker = yes)

Age Category	Age Score
0-19	0
20-39	9
40 - 60	11
60 +	10
BMI Category	BMI Score
Normal	0
Underweight	3
Overweight	3
Obese	4
Morbidly Obese	9

**Supplementary Table 6 (S6):** Prevalence of symptoms (n, %) by subgroup in the pre-pandemic, acute, and post-acute phase.

	Pre-pand	lemic phase	e, n (%)	Acute ph (%)	Post- acute phase, n (%)		
	PCC	Non-	COVID-	Community	PCC	Non-	PCC
	patients	PCC	19	controls	patients	PCC	patients
	(n=160)	cases	positive	(n=75)	(n=160)	cases	(n=160)
		(n=254)	cohort			(n=254)	
			(n=414)				
Chest pain	12 (7.5)	12 (4.7)	24 (5.8)	3 (4.0)	81	59	52
<b>^</b>					(50.6)	(23.2)	(32.5)
Concentration	10 (6.3)	13 (5.1)	23 (5.6)	2 (2.7)	80 (50)	46	65
problems <sup>B</sup>						(18.1)	(40.6)
Cough <sup>B</sup>	13 (8.1)	31	44 (10.6)	5 (6.7)	120	129	78
		(12.2)			(75.0)	(50.8)	(48.8)
Fatigue <sup>B</sup>	15 (9.4)	20 (7.9)	35 (8.5)	7 (9.3)	136	121	107
_					(85.0)	(47.6)	(66.9)
Headache <sup>B</sup>	33	52	85 (20.5)	9 (12.0)	124	154	79
	(20.6)	(20.5)			(77.5)	(60.6)	(49.4)
Heart	13 (8.1)	9 (3.5)	22 (5.3)	2 (2.7)	56	35	37
palpitations <sup>B</sup>					(35.0)	(13.8)	(23.1)
Loss of	6 (3.8)	11 (4.3)	17 (4.1)	3 (4.0)	113	113	96
appetite <sup>B</sup>					(70.6)	(44.5)	(59.4)
Reduced	8 (5.0)	4 (1.6)	12 (2.9)	5 (6.7)	122	98	81
muscle					(76.2)	(38.6)	(50.6)
strength <sup>B</sup>							
Loss of sense	5 (3.1)	9 (3.5)	14 (3.4)	0 (0)	97	118	62
of smell <sup>B</sup>					(60.6)	(46.5)	(38.8)
Loss of sense	3 (1.9)	9 (3.5)	12 (2.9)	0 (0)	105	126	61
of taste <sup>B</sup>					(65.6)	(49.6)	(38.1)
Muscle ache <sup>B</sup>	17	14 (5.5)	31 (7.5)	8 (10.7)	114	102	72
	(10.6)				(71.2)	(40.2)	(45.0)
Reduced	12 (7.5)	6 (2.4)	18 (4.3)	4 (5.3)	133	117	105
physical					(83.1)	(46.1)	(65.6)
endurance <sup>A, B</sup>							
Shortness of	20	15 (5.9)	35 (8.5)	3 (4.0)	107	86	95
breath <sup>A, B</sup>	(12.5)				(66.9)	(33.9)	(59.4)
Sleeping	20	20 (7.9)	40 (9.7)	6 (8.0)	98	75	66
problems <sup>B</sup>	(12.5)				(61.3)	(29.5)	(41.2)

<sup>A</sup> Statistically significant difference between PCC patients and non-PCC cases (p<0.05) in the prepandemic phase, with Fisher's exact test. <sup>B</sup> Statistically significant difference between PCC patients and non-PCC cases (p<0.05) in the acute phase, with Fisher's exact test.

<sup>C</sup> Statistically significant difference between PCC patients and community controls (p<0.05) in the pre-pandemic phase, with Fisher's exact test (does not occur).

<sup>D</sup> Statistically significant difference between COVID-19 positive cases and community controls (p<0.05) in the pre-pandemic phase, with Fisher's exact test (does not occur).

	Chest pain (n=52)	Concentration problems (n=65)	Cough (n=78)	Fatigue (n=107)	Headache (n=79)	Heart palpitations (n=37)	Loss of appetite (n=95)	Reduced muscle strength (n=81)	Loss of sense of smell (n=62)	Loss of sense of taste (n=61)	Muscle ache (n=72)	Reduced physical endurance (n=105)	Shortness of breath (n=95)	Sleeping problems (n=66)
Age group (years), n (	%)	1	1	1	1	1	1	1	1	1	1	1		
0 - 19 (n=6)	1 (17)	1 (17)	5 (83)	4 (67)	5 (83)	0 (0)	2 (33)	2 (33)	2 (33)	0 (0)	1 (17)	2 (33)	1 (17)	0 (0)
20-39 (n=61)	23 (38)	22	27	40	30	13	35	29	21	24	25	39	40	21
		(36)	(44)	(66)	(49)	(21)	(57)	(48)	(34)	(39)	(41)	(64)	(66)	(34)
40-59 (n=64)	12 (19)	28	26	40	28	11	36	31	23	22	25	41	34	27
		(44)	(41)	(63)	(44)	(17)	(56)	(48)	(36)	(34)	(39)	(64)	(53)	(42)
60+ (n <b>=</b> 29)	16 (55)	14	20	22	16	13	22	19	16	15	21	23	20	18
		(48)	(69)	(76)	(55)	(45)	(76)	(66)	(55)	(52)	(72)	(79)	(69)	(62)
Sex, n (%)														
Female (n=114)	42 (37)	50	57	79	60	30	70	57	44	46	52	74	71	53
		(44)	(50)	(69)	(53)	(26)	(61)	(50)	(39)	(40)	(46)	(65)	(62)	(46)
Male (n=46)	10 (22)	15	21	28	19	7 (15)	25	24	18	15	20	31	24	13
		(33)	(46)	(61)	(41)		(54)	(52)	(39)	(33)	(43)	(67)	(52)	(28)
BMI category (kg/m <sup>2</sup> ),	n (%)	1	1	1	1	1	1	1	1	1	1	1	1	1
Underweight (n=2)	0 (0)	0 (0)	2	1 (50)	1 (50)	0 (0)	0 (0)	0 (0)	1 (50)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
			(100)											ļ
Normal (n=32)	6 (19)	14	12	20	16	4 (13)	13	18	14	13	12	22	14	11
		(44)	(38)	(63)	(50)		(41)	(56)	(44)	(41)	(38)	(69)	(44)	(34)

Supplementary Table 7 (S7): The prevalence of post-acute symptoms across different baseline characteristics of PCC patients (n=160).

Overweight (n=41)	14 (34)	14	23	25	16	7 (17)	23	18	16	14	17	25	23	16
Ohaaa (n-26)	12 (26)	(34)	(30)		(39)	8 (22)	(30)	(44)	(39)	(34)	(41)	(01)	(30)	(39)
Obese (II=50)	15 (50)	(61)	(42)	(61)	(50)	0(22)	(60)	(42)	(28)	(36)	(36)	(56)	(58)	(31)
Morbidly obese	10 (30)	26	(42)	30	28	18	3/	30	21	21	30	38	38	21
(n-40)	19 (39)	(53)	(53)	(80)	(57)	(37)	(60)	(61)	(43)	(13)	(61)	(78)	(78)	(13)
Comorbidities n (%)		(33)	(33)	(80)	(37)	(37)	(09)	(01)	(43)	(43)	(01)	(78)	(78)	(43)
Ves one or more	13 (39)	1/	23	24	11	9 (27)	10	20	16	1/	18	26	25	16
(n=33)	15 (57)	(42)	(70)	(73)	(33)	)(21)	(58)	(61)	(48)	(42)	(55)	(79)	(76)	(48)
No $(n=127)$	39 (31)	51	55	83	68	28	76	61	46	48	54	79	70	50
	0) (01)	(40)	(43)	(65)	(54)	(22)	(60)	(48)	(36)	(38)	(43)	(62)	(55)	(39)
Smoking, n (%)		()	(12)	(00)			(00)	()	(00)	(00)	(12)	()	()	(0,2)
Yes (n=18)	6 (33)	6 (33)	12	10	9 (50)	4 (22)	14	7 (39)	7 (39)	8 (44)	5 (28)	11	10	6 (33)
	- ( )	- ( /	(67)	(56)			(78)					(61)	(56)	
No (n=142)	46 (32)	59	66	97	70	33	81	74	55	53	67	94	85	60
	~ /	(42)	(46)	(68)	(49)	(23)	(57)	(52)	(39)	(37)	(47)	(66)	(60)	(42)
Alcohol use, n (%)														
Yes (n=109)	33 (30)	44	52	69	50	20	65	52	42	41	44	71	63	42
		(40)	(48)	(63)	(46)	(18)	(60)	(48)	(39)	(38)	(40)	(65)	(58)	(39)
No (n=51)	19 (37)	21	26	38	29	17	30	29	20	20	28	34	32	24
		(41)	(51)	(75)	(57)	(33)	(59)	(57)	(39)	(39)	(55)	(67)	(63)	(47)
Education level, n (%)														
Low (n=119)	40 (34)	47	61	82	62	31	75	61	48	47	60	81	69	52
		(39)	(51)	(69)	(52)	(26)	(63)	(51)	(40)	(39)	(50)	(68)	(58)	(44)
Moderate (n=23)	7 (30)	11	10	16	10	3 (13)	11	13	7 (30)	8 (35)	9 (39)	16	15	9 (39)
		(48)	(43)	(70)	(43)		(48)	(57)				(70)	(65)	
High (n=17)	5 (29)	7 (41)	7 (41)	9 (53)	7 (41)	3 (18)	8 (47)	7 (41)	7 (41)	6 (35)	3 (18)	7 (41)	11	5 (29)
													(65)	
Hospitalized during ac	ute phase, n	(%)												
Yes (n=24)	6 (25)	15	12	16	9 (38)	6 (25)	17	17	7 (29)	7 (29)	13	21	19	10
		(63)	(50)	(67)			(71)	(71)			(54)	(88)	(79)	(42)
No (n=136)	46 (34)	50	66	91	70	31	78	64	55	54	59	84	76	56
		(37)	(49)	(66)	(51)	(23)	(57)	(47)	(40)	(39)	(43)	(61)	(56)	(41)
GP visit during acute phase, n (%)														

Yes (n=14)	6 (43)	7 (50)	10	11	6 (43)	5 (36)	9 (64)	7 (50)	8 (57)	9 (64)	5 (36)	11	10	11
			(71)	(79)								(79)	(71)	(79)
No (n=146)	46 (32)	58	68	96	73	32	86	74	54	52	67	94	85	55
		(40)	(47)	(66)	(50)	(22)	(59)	(51)	(37)	(36)	(46)	(64)	(58)	(38)

**Supplementary Table 8 (S8):** Characteristics of SARS-CoV-2 positive cases (n= 390) included in risk scoring

	PCC patients (n=156)	Non-PCC cases (n= 234)	P-value
Age group (years), n (%	<b>(0)</b>		
0-19 years	6 (34%)	31 (13%)	0.01 <sup>B</sup>
20-39 years	61 (39%)	90 (39%)	
40-59 years	63 (40%)	80 (34%)	
60 + years	26 (17%)	33 (14%)	
Sex, n (%)		·	<0.01 <sup>B</sup>
Male	45 (29%)	107 (46%)	
Female	111 (71%)	127 (54%)	
Comorbidities, n (%)			0.04 <sup>B</sup>
Yes	30 (19%)	27 (12%)	
No	126 (81%)	207 (89%)	
GP visit in acute phase,	, n (%)		0.02 <sup>B</sup>
Yes	14 (9%)	8 (3%)	
No	142 (91%)	226 (97%)	
Hospitalized for COVI	D-19 in acute phase, n (%	ó)	<0.01 <sup>B</sup>
Yes	22 (14%)	6 (23%)	
No	134 (86%)	228 (97%)	
Median number of	10 (5)	5 (7)	<0.01 <sup>A</sup>
symptoms in acute			
phase (IQR)			
Pre-pandemic alcohol u	ise	1	0.81 <sup>B</sup>
Yes	106 (68%)	148 (63%)	
No	50 (32%)	86 (37%)	
Pre-pandemic smoking	1	1	0.63 <sup>B</sup>
Yes	18 (12%)	32 (14%)	
No	138 (89%)	202 (86%)	
BMI (kg/m <sup>2</sup> ) category	1	1	<0.01 <sup>B</sup>
Underweight	2 (1%)	4 (2%)	
Normal	32 (21%)	75 (32%)	_
Overweight	40 (26%)	70 (30%)	_
Obese	35 (22%)	48 (21%)	
Morbidly obese	47 (30%)	37 (16%)	
Education level	1	1	0.08 <sup>B</sup>
Low	116 (74%)	194 (83%)	
Moderate	24 (15%)	27 (12%)	
High	17 (11%)	13 (6%)	

tool analyses.

<sup>A</sup> Wilcoxon test. <sup>B</sup> Fisher's exact test.

## SUPPLEMENTARY FIGURES



**Supplementary Figure 1 (SF1):** Epicurve and inclusion period for SARS-CoV-2 positive cases on Bonaire, Caribbean Netherlands.

Epidemiological curve of the SARS-CoV-2 outbreak on Bonaire, Caribbean Netherlands, displaying the weekly number of confirmed cases by 4-week intervals from the start of the pandemic until 27 October 2021. In this study, we included permanent residents of Bonaire, who had a SARS-CoV-2 positive test result between the start of the pandemic in 2020 until 1 October 2021.

Source: Data from RIVM (downloaded on 20 January 2023)



**Supplementary Figure 2 (SF2):** Internal calibration plots for predicting the risk of PCC PCC in COVID-19 patients.

Internal calibration plots for predicting the risk of PCC in COVID-19 patients. Dashed lines show ideal calibration, dotted line shows apparent calibration and the solid line shows bias-corrected calibration. (A). Sparse risk scoring tool based on full patient sample. (B) Sparse risk scoring tool based on non-hospitalized sample. (C) Rich risk scoring tool based on full patient sample. (D) Rich risk scoring tool based on non-hospitalized sample

**Supplementary Figure 3 (SF3):** Receiver Operating Characteristic (ROC) curves for PCC risk scoring tools.



Receiver Operating Characteristic (ROC) curves for PCC risk scoring tools (A). Sparse risk scoring tool based on full patient sample. (B) Sparse risk scoring tool based on non-hospitalized sample. (C) Rich risk scoring tool based on full patient sample. (D) Rich risk scoring tool based on non-hospitalized sample.